Boronic acid/boronate prodrugs for cancer treatment: current status and perspectives.

Maslah, Hichem; Pethe, Stéphanie; Labruère, Raphaël

Maslah, Hichem; Pethe, Stéphanie; Labruère, Raphaël.

Affiliation

Maslah H; Université Paris-Saclay, CNRS, Institut de chimie moléculaire et des matériaux d'Orsay, Orsay, 91405, France.
Pethe S; Université Paris-Saclay, CNRS, Institut de chimie moléculaire et des matériaux d'Orsay, Orsay, 91405, France.
Labruère R; Université Paris-Saclay, CNRS, Institut de chimie moléculaire et des matériaux d'Orsay, Orsay, 91405, France.

Future Med Chem ; 13(10): 859-861, 2021 05.

Article in En | MEDLINE | ID: mdl-33845596

Subject(s)

Antineoplastic Agents/pharmacology; Boronic Acids/pharmacology; Neoplasms/drug therapy; Prodrugs/pharmacology; Antineoplastic Agents/chemistry; Boronic Acids/chemistry; Humans; Neoplasms/metabolism; Neoplasms/pathology; Prodrugs/chemistry; Reactive Nitrogen Species/metabolism; Reactive Oxygen Species/metabolism; Tumor Microenvironment/drug effects

Key words

anticancer chemotherapy; boronic acids and boronates; prodrug; reactive nitrogen oxide species; reactive oxygen species

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Boronic Acids / Prodrugs / Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: Future Med Chem Year: 2021 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google